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Abstract
Background: Severe limb ischaemia is defined by ischaemic rest/night pain, tissue loss, or both, secondary to
arterial insufficiency and is increasingly caused by infra-popliteal (below the knee) disease, mainly as a result of the
increasing worldwide prevalence of diabetes. Currently, it is unknown whether vein bypass surgery or the best
endovascular treatment (angioplasty or stenting) represents the optimal revascularisation strategy in terms of
amputation-free survival, overall survival, relief of symptoms, quality of life and cost-effective use of health care
resources.
Methods/Design: The Bypass vs. Angioplasty in Severe Ischaemia of the Leg - 2 Trial is a UK National Institute of
Health Research, Health Technology Assessment funded, multi-centre randomised controlled trial that compares, at
the point of clinical equipoise, the clinical and cost-effectiveness of a ‘vein bypass first’ and a ‘best endovascular
treatment first’ revascularisation strategy for severe limb ischaemia due to infra-popliteal disease. The primary
clinical outcome is amputation-free survival defined as the time to major (above the ankle) amputation of the trial
limb or death from any cause. The primary outcome for the cost-effectiveness analysis is cost per quality-adjusted
life year. Secondary outcomes include overall survival, quality of life, in-hospital mortality and morbidity, repeat and
crossover interventions, healing of tissue loss and haemodynamic changes following revascularisation. Sample size
is estimated at 600 patients. An economic evaluation will be conducted from the perspective of the National Health
Service and comprise a ‘within-study’ analysis, based on prospectively collected trial data and a ‘model-based’
analysis, which will extrapolate and compare costs and effects beyond the study follow-up period.
Discussion: The BASIL-2 trial is designed to be pragmatic and represent current practice within the United
Kingdom. Patients with severe limb ischaemia can only be randomised into the trial where clinical equipose exists.
The advent of hybrid operating procedures should not be a barrier to randomisation, should a patient require
inflow correction prior to tibial revascularisation.
Trial registration: ISRCTN:27728689 Date of registration: 12 May 2014.
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Background
As a result of smoking, diabetes, high blood pressure, high
cholesterol, kidney failure, and old age, some people de-
velop atherosclerosis (aka ‘hardening of the arteries) in
their legs.
This atherosclerosis narrows and eventually blocks
their arteries, thereby reducing the blood supply to their
legs and feet: a condition termed ‘ischaemia’.
Advanced cases are known as ‘severe limb ischaemia’
and cause one or both of the following problems:
1) Injuries to the foot fail to heal, allowing infection to
enter the tissues, resulting in the development of
ulceration, and even gangrene.
2) Severe constant pain in the foot, which is often
worse at night and disturbs the sleep.
In the developed world, the incidence of critical or
severe limb ischaemia is estimated at 500 to 1,000 per
million population [1].
The number of people affected by severe limb ischaemia
is increasing worldwide as a result of the ageing popula-
tion, the increase in diabetes, and the continuing high
rates of smoking [2].
In people with severe limb ischaemia, if the blood sup-
ply to the leg is not restored (revascularisation), then the
risks of amputation and death are high. In the UK, ap-
proximately 5,000 to 6,000 amputations are performed
each year, the great majority for severe limb ischaemia [3].
1) In addition to best medical therapy (comprising
anti-platelet and lipid modifying agents, optimal
diabetic control, analgesia, and foot and wound
care), which all patients should receive as indicated,
severe limb ischaemia can be managed by means of
the following:
2) Primary amputation, when the limb is beyond
salvage and/or the patient is unfit/unwilling/unable
to undergo revascularisation.
3) Surgical revascularisation, which is usually
undertaken by means of a bypass fashioned using an
autologous vein and/or endarterectomy.
4) Endovascular revascularisation, which is a ‘keyhole’
procedures performed through the groin under local
anaesthetic and using balloons and stents to force/
hold open the arteries.
The current evidence base underpinning the treatment
of severe limb ischaemia is extremely poor with very few
randomised clinical trials [4] and no available systematic
reviews or meta-analysis.
The National Institute of Health and Care Excellence
clinical guideline (CG) 147 on Peripheral Arterial Disease
recommended that a randomised controlled trial be
undertaken to answer the following question which
BASIL-2 aims to answer: namely, ‘What is the clinical and
cost effectiveness of a 'bypass surgery first' strategy com-
pared with an 'angioplasty first' strategy for treating people
with critical limb ischaemia caused by disease of the infra-
geniculate (below the knee) arteries?’ [5]
Aims
The original BASIL-1 trial, on which BASIL-2 is based,
randomised 452 patients with severe limb ischaemia,
mainly due to femoro-popliteal disease (in the thigh), to
either an angioplasty first or a bypass surgery first revas-
cularisation strategy [4]. The Bypass vs. Angioplasty in
Severe Ischaemia of the Leg - 2 (BASIL-2) Trial is a UK
National Institute of Health Research, Health Technology
Assessment funded, multi-centre randomised controlled
trial (http://www.nets.nihr.ac.uk/projects/hta/123545) that
will now compare, at the point of clinical equipoise, the
clinical and cost-effectiveness of a ‘vein bypass first’ with a
‘best endovascular treatment first’ revascularisation strat-
egy for severe limb ischaemia due to infra-popliteal (below
the knee) disease (Fig. 1). BASIL-2 includes an internal
pilot phase and economic analysis. The primary clinical
outcome is amputation free survival defined as the time to
major (above the ankle) amputation of the index (trial)
limb or death from any cause, whichever comes first. The
primary outcome for the cost-effectiveness analysis will be
cost per quality-adjusted life year. Secondary outcome
measures are shown in Table 1.
Methods
Ethics
Ethical approval was gained via the National Research
Ethics Service, West Midlands, UK (Coventry and
Warwick) on 3 March 2014 (reference 14/WM/0057).
Each patient will provide fully informed, written con-
sent prior to randomisation.
Eligibility
All patients with severe limb ischaemia referred to vascu-
lar units within participating NHS Trusts can be consid-
ered. To be eligible for randomisation, patients must have
adequate inflow to support infra-popliteal intervention, an
anticipated life expectancy greater than 6 months, capacity
to consent, and be able to speak English where translation
facilities are unavailable (Table 2). Previous intervention to
the trial leg is not an exclusion criterion.
Potentially eligible patients will be discussed at a formally
minuted multi-disciplinary meeting comprising vascular
surgeons and interventional radiologists. If the patient is
deemed suitable for both treatment arms and there is clin-
ical equipoise as to which revascularisation strategy is most
appropriate, they will be invited to enter the trial.
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BASIL 2 TRIAL DESIGN
Randomisation
Diagnostic imaging, blood tests and PEDIS completed
Patient presents with severe limb ischaemia (SLI) due to
infra-geniculate (IG), with or without femoro-popliteal (FP), arterial disease
Rest pain and/or tissue loss due to IG +/-FP disease 
Patient requires, is suitable for, and is willing to undergo early revascularisation by means     
of IG +/ - FP vein bypass surgery or endovascular treatment 
Consultant Interventionalist willing to perform endovascular treatment (balloon angioplasty+/-
Research nurse discusses trial with patient and gives  
out the patient information sheet to allow patient to fully  
consider entry into the trial
Informed consent obtained from patient and 
documented via completion of a written consent form
Research nurse completes randomisation notepad, patient completes HRQoL forms 
‘Endovascular treatment (balloon 
angioplasty+/-stenting) first’ strategy
Follow-up by research nurses at 1, 3, 6, 9, 12, 18, 24,  
30, and 36 months after randomisation
Each assessment comprises: status of patient (death  
and cause) and trial leg (major amputation),pulses,  
ankle pressures, toe pressures,pain score, medication 
review, healing of tissue loss and minor amputations, 
HRQ L, primary and secondary healthcare and social 
care usage and costs, other morbidity, crossover and  
re-interventions
Late follow-up conducted through national 
registries and case record review
Major amputation/death
Economic analysis Economic analysis
Major amputation/death
Screening consent signed and screening log completed to 
determine if patient should be randomised into the trial.
Screening failed, 
do not enter patient 
into the trial
Screening passed, enter patient into the trial 
Surger y within 
2 weeks of 
randomisation
stenting) first and Consultant Surgeon willing to perform vein bypass surgery first
‘Vein bypass surgery first’ strategy
Fig. 1 The BASIL-2 CONSORT diagram
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Randomisation
Blinding of the clinician and patient in this trial is not
possible due to the completely different natures of the
treatments allocated.
Randomisation is provided by a web-based third party
service with a telephone option if required. The first 30
patients shall be allocated randomly, subsequently four
out of every five patients are minimised, with 1 in 5 pa-
tients randomly allocated using random block without
regular spacing. The following minimisation variables
will be used:
 age (≤60, 61 to 70, 71 to 80, > 80 years),
 sex (male or female),
 diabetes mellitus and chronic kidney disease*
(diabetes mellitus, chronic kidney disease, both or
neither, where chronic kidney disease is defined as
stage 3 or worse, based on estimated glomerular
filtration rate of < 60 (ml/min/1.73 m2), and
 severity of clinical presentation (rest/night pain
only, tissue loss only, or both).
Baseline assessment
After randomisation patients undergo a baseline assess-
ment comprising the following:
1. Patient history including risk factors for vascular
disease, co-morbidities, previous arterial interventions
to either leg, amputations and coronary interventions.
2. Physical examination including assessment of
functional status, peripheral pulses, ankle-brachial
pressure index and toe-brachial pressure index.
3. Review of investigations including imaging and
results of blood tests.
4. Foot assessment using the Wound Ischaemia Foot
Infection (WIFI) [6] and Perfusion Extent Depth
Ischaemia Sensation (PEDIS) [7].
5. Assessment of Quality of Life using the Visual
Analogue Scale, European Quality of life 5 level
score, Short Form-12, ICEpop Capability for Older
people, Vascular Quality of life, and Hospital Anxiety
and Depression Scale.
The allocated intervention should be performed within
14 days where clinically and logistically possible.
Trial interventions
Vein bypass will be performed using standard anaesthetic
and surgical techniques. The type of vein used, and the
location of the proximal and distal anastomoses, will be
recorded. Best endovascular treatment will usually be per-
formed under local anaesthetic via the common femoral
artery. Success of vein bypass and best endovascular treat-
ment will be assessed by pulse status, completion angiog-
raphy and haemodynamic measures such as ankle brachial
pressure index.
Table 1 BASIL-2 secondary outcomes
Overall survival
In-hospital and 30-day morbidity and mortality
Major adverse limb event – amputation (transtibial and above) or any
major vascular re-intervention (thrombectomy, thrombolysis, balloon
angioplasty, stenting or surgery)
Major adverse cardiovascular event – (severe limb ischaemia and
amputation affecting the contralateral limb, acute coronary syndrome,
or stroke)
Relief of ischaemic pain (visual analogue scale and medication usage)
Psychological morbidity (Hospital Anxiety and Deprivation Score)
Quality of life using generic (European Quality of life 5 level
questionnaire, Short Form-12, ICEpop CAPability for older people and
disease specific Vascular Quality of Life) tools
Re- and cross-over intervention rates
Healing of tissue loss (ulcers, gangrene) of presumed arterial aetiology
as assessed by the Perfusion Extent Depth Infection Sensation [6] and
Wound Ischaemia Foot Infection [7] scoring and classification systems
Extent and healing of minor (toe and forefoot) amputations (also using
the above wound scoring systems)
Haemodynamic changes: absolute ankle and toe pressure, (ankle
brachial pressure index and toe brachial pressure index).
Table 2 BASIL-2 inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Have severe limb ischaemia due to infra-popliteal, +/− femoropopliteal disease Have an anticipated life expectancy of < 6 months
Be judged by responsible clinicians (consultant vascular surgeon, interventional
radiologist, and diabetologists) working as part of a multi-disciplinary team to require
early revascularisation in addition to best medical therapy, foot and wound care.
Are unable to provide consent due to incapacity
Have adequate inflow to support the randomised infra-popliteal intervention
(if not, patients can be randomised to have their allocated infra-popliteal
intervention at the same time or after the inflow procedure).
Are a non-English speaker where translation services are
inadequate to provide informed consent
Be judged suitable for both vein bypass and best endovascular treatment following
diagnostic imaging and a formal documented multi-disciplinary team meeting.
Are judged unsuitable for either revascularisation strategy
by the responsible clinician
Tissue loss considered to be primarily of venous aetiology
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Follow-up
Outcomes will be recorded at 1 month after intervention
and at 3, 6, 9, 12, 24, 30, and 36 months after random-
isation (Fig. 2). Information collected will include further
interventions (vascular or non-vascular), hospitalisations
(for whatever reason), other health problems, clinical
and haemodynamic status of trial and non-trial limbs,
functional status and quality of life assessments. The re-
cording of Adverse Events and Serious Adverse Events
will conform to the Good Clinical Practice standards
and the Research Governance Framework 2005 [8, 9].
After delivery of the randomised intervention, all subse-
quent interventions will be at the discretion of the
clinical team in the patient’s best interests.
Sample size calculation
Sample size allocation was calculated on a time-to-event
analysis, undertaken at 2 years post randomisation. Re-
cruitment is aiming to take place over 3 years with 20 %
recruited in the first year and 40 % recruited in each
subsequent year. Non-event rates for amputation-free sur-
vival are assumed to be 0.72, 0.62, 0.53, 0.47 and 0.35 at
years 1 to 5 based on data from the original BASIL-1 trial
[4]. Allowing for a conservative estimate of 10 % drop-out
rate for the primary outcome, a trial of 600 patients will
have 90 % power to detect a reduction in amputation-free
survival of one third (HR = 0.66 equivalent to an absolute
difference of 12 % in amputation free survival at Year 3)
with a 5 % significance level.
Pilot phase
Recruitment will be reviewed at the end of a 12 month pilot
phase. The following are proposed as criteria on which to
base a decision to discontinue the trial at that stage:
 Less than 2/3 of the centres recruiting.
 Fewer than 60 patients randomised in total.
 Less than 2/3 of centres recruiting fewer than two
patients per month after month 4 onward.
Completed Form Screen Baseline Randomization
Intevention (initial 
within 2 weeks)
Follow-up 
months 1, 3, 6, 
9, 12, 18, 24,36
Informed Consent Patient
History Case Notes/Patient
Physical Case Notes
Imaging Case Notes
Wound Assessment Case Notes
Ischaemic Pain VAS Patient
WiFI Case Notes
HADS Patient
EQ-5D-5L Patient
SF-12 Patient
ICECAP-O Patient
VascuQoL Patient
Haemodynamic changes Case Notes
Case Notes
Amputation assessment* If 
Form Case Notes/Patient
Randomization Case Notes
If applicable complete an 
intervention form Case Notes/Patient
Resource Usage* If applicable 
complete an In-Patient Form Case Notes/Patient
Case Notes/Patient
SAE Review Case Notes/Patient
Ulcer and gangrene assessment
applicable complete Amputation 
Vascular re-intervention review* 
Pain Relief Medication Review
Fig. 2 The BASIL-2 assessment schedule
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 Less than 80 % of patients have received their
allocated treatment.
At the end of the pilot phase, the completeness of the
quality-of-life data will also be assessed. If completion
rates are poor, then consideration will be given to dis-
continuing the Hospital Anxiety and Depression Scale
and ICEpop CAPability for older people tools.
Repeat and cross-over interventions
Repeat and cross-over interventions are permitted in
either arm of the trial if the primary intervention is
unsuccessful. After reviewing the data from the
original BASIL trial [4], we estimate a 20 % re-
intervention rate, which we believe is more likely to
occur in the best endovascular treatment arm and
within the first 12 months of the primary interven-
tion. Data will be collected on all re-interventions.
Re-intervention rates will be compared in a secondary
analysis (the trial is powered at 90 % to detect a two-
fold difference of 10 % versus 20 %).
Subgroup analysis
Subgroup analysis will be used to detect treatment ef-
fects between pre-specified variables, focusing on effects
on survival and repeated measures models (Table 3).
Economic evaluation
An economic evaluation will be undertaken to deter-
mine the relative cost-effectiveness of the ‘vein bypass
first’ and ‘best endovascular first’ revascularisation strat-
egies with a view to informing clinical decision-making
within the NHS. The economic analysis will consist of
two components: a ‘within-study’ analysis which will be
based on study end-points and a ‘model-based’ analysis
which will extrapolate and compare costs and effects
likely to accrue beyond the study follow-up period. The
analysis will be presented in terms of cost per additional
quality-adjusted life year gained and cost per year of
amputation-free survival. In line with existing recommen-
dations, the base-case analysis will adopt a health care sys-
tem (payer’s) perspective by considering costs incurred by
the NHS and personal social services. Costs will be
calculated on the basis of patient-level data related to (a)
the procedures under assessment; (b) hospital stay and re-
admissions, and (c) post-discharge use of National Health
Service and social services. Procedure-related costs will be
estimated in a separate micro-costing study. If plausible,
additional analyses will be undertaken from a wider
societal perspective. Quality of life will be derived from
patients’ responses to the EuroQol EQ-5D-5 L [10] instru-
ment and will be translated into preference-based quality
of life indices using a UK-specific valuation set [11]. In
addition to the trial-based evaluation, a model-based ana-
lysis will be conducted to consider the costs and benefits
likely to accrue over a lifetime time horizon. Both deter-
ministic and probabilistic sensitivity analyses will be
undertaken to explore the robustness of the obtained
results to sample variability and plausible variations in key
assumptions and employed analytic methods [12].
Interim analyses
Interim analyses will be performed on an annual basis. A
Haybittle-Peto approach will be used where all interim
analyses use a difference of three standard errors as a
stopping guideline. These analyses will be reviewed by the
independent data monitoring committee on an annual
basis or more frequently if required.
Differences in the primary clinical outcome (amputa-
tion-free survival) will be assessed by comparing time
from randomisation to major (above ankle) limb ampu-
tation or death from any cause (whichever occurs first)
between the two arms. Primary analysis will use Kaplan-
Meier plots and test the difference between two arms
using the log-rank test. Data will be censored when indi-
viduals reach the end of follow-up or are lost to follow-
up before incurring the primary outcome.
Further analysis of the primary outcome will involve the
fitting of flexible parametric survival models to estimate
both relative and absolute differences in hazard of the pri-
mary outcome to model the underlying differences in haz-
ard and to allow for non-proportional hazards. The
addition of covariates to the model, derived from the
minimisation variables (age, sex, presence or absence of
chronic kidney disease, diabetes and tissue loss) will allow
baseline adjustments and the ability to test for further sub-
group effects. The primary analysis will be performed on
an intention to treat basis taking into consideration the
first allocated method of revascularisation, regardless of
cross-over or repeat interventions.
Secondary outcome measures that are based on
continuous scales will be examined using a repeated
measures multi-level model to examine the effects
over time. Treatment effects will be reported from
these measures at 1 and 12 months from randomisa-
tion and at the end of the study. Other outcomes will
be measured using standard statistical methods, such
Table 3 BASIL-2 sub-group analysis
Rest pain versus tissue loss versus both
Diabetes mellitus
CKD
Haemodynamic measurements
Alternative endovascular options
Differences in resource usage and outcome between alternative
endovascular options
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as Fisher’s exact test for categorical data and log-rank
for time to event data. All of these analyses will be
performed using the intention to treat principle with
95 % confidence intervals with associated p-values.
Discussion
The trial is designed to be pragmatic and representa-
tive of the ‘real world’ NHS management of severe limb
ischaemia due to infra-popliteal disease. Many of these
patients will have multi-level disease including ‘inflow’
or aorto-iliac disease, which may need to be corrected
prior to randomisation. With the evolution of hybrid
operating it would be permissible to perform an on-
table inflow procedure (to popliteal, knee, level) at the
same time as the randomised infra-popliteal interven-
tion. Alternatively, an inflow procedure to popliteal
(knee) level can be performed first and the patient then
randomised if further infra-popliteal intervention is
considered necessary.
Data from the original BASIL-1 trial [4] suggests that up
to 25 % of patients may present with bilateral severe limb
ischaemia. Bilateral simultaneous revascularisation is rare.
It is usually clinically obvious which leg requires revascular-
isation first. Only one leg can be randomised in BASIL-2.
Patients can only be randomised if clinical equipoise
exists. Local variations in practice may influence such
decisions with some centres likely to favour an endovas-
cular intervention strategy and others preferring surgical
bypass. Current evidence does not support either an
endovascular first or bypass first strategy and unless an
obvious clinical reason is evident (such as lack of vein
conduit, unsuitability for a surgical intervention due to
comorbid state) all patients who are suitable for both
arms could, theoretically be randomised into the trial.
Trial status
The BASIL-2 trial is currently open for recruitment in
multiple UK-based centres and has randomised more
than 100 patients at the time of publication.
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